deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessablestatistically conclusive-34%--